Cellerix, S.A.;Consejo Superior de Investigaciones Cientificas (CSIC)
发明人:
申请号：
EP17154939.7
公开号：
EP3184630A1
申请日:
2006.09.22
申请国别(地区):
EP
年份:
2017
代理人:
摘要：
The present invention provides a population of connective tissue derived cells that respond to interferon-gamma (IFN-γ) by expressing indolamine-2,3-dioxygenase (IDO) for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, including, but not limited to, autoimmune diseases, inflammatory disorders, and immunologically mediated diseases including rejection of transplanted organs and tissues.
